Optimizing Asparaginase Use in Acute Lymphoblastic Leukemia: A Comprehensive Program on Safety and Efficacy

Program Description
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy that involves proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs. Current treatment regimens for ALL consist of multiple chemotherapy agents delivered throughout several distinct phases of therapy. The addition of asparaginase to these regimens has led to improvements in remission rates and increased survival for patients with ALL. As part of the multidisciplinary care team, oncology pharmacists contribute to improved patient outcomes and help ensure the safe and effective use of systemic therapies. Through this activity, pharmacists will be equipped with the knowledge necessary to effectively monitor patients with ALL for asparaginase-associated toxicities as well as ensure proper management of hypersensitivity reactions and other adverse effects.

Target audience: Oncology pharmacists
Type of activity: Application
Release date: December 13, 2023
Expiration date: December 13, 2024
Time to complete activity: 1.0 hour
Learner level: Foundational; Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore asparaginase-containing regimens for adults/young adults with acute lymphoblastic leukemia (ALL) considering guideline recommendations and recent clinical evidence
• Identify appropriate strategies to minimize hypersensitivity reactions of asparaginase therapy in adult/young adult patients with ALL, in accordance with guideline-recommended protocols
• Classify the pharmacist’s role in preventing, monitoring, and managing asparaginase-related adverse effects in adult/young adult patients with ALL

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-452-H01-P. The activity is available for CE credit through December 13, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Anthony J. Perissinotti, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Servier, Pfizer, Amgen

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms